Targeted viral therapy destroys breast cancer stem cells in preclinical experiments
The study, published in the International Journal of Cancer, focuses on a gene originally cloned in the laboratory of primary investigator Paul B. …
The study, published in the International Journal of Cancer, focuses on a gene originally cloned in the laboratory of primary investigator Paul B. …
Researchers at the Max Planck Institute for Infection Biology in Berlin (MPIIB) now show that Chlamydia infections can cause mutations in the host DNA by overriding the normal mechanisms by which their host prevents unregulated growth of genetically damaged cells that pave the way for the development of cancer. Owing to their intracellular lifestyle Chlamydia depend on various host cell functions for their survival. Chlamydia manipulates the host cell mechanism to favour its growth, however the consequences of such alterations on the fate of host cells remains enigmatic…
The results will be presented Monday at The Endocrine Society’s 95th Annual Meeting in San Francisco. "Our novel prostate cancer drug works by a unique mechanism of action," said study lead author Jeremy Jones, PhD, assistant professor of molecular pharmacology at City of Hope, Beckman Research Institute, in Duarte, CA. "Thus, it has the potential to treat cancers resistant to currently approved therapies." Prostate cancer is the second-leading cause of cancer death, after lung cancer, among men in the United States, according to the American Cancer Society. The disease affects about one out of every six men, and more than 29,000 will die of prostate cancer this year alone. …
Among girls, puberty generally begins between the ages of 10 and 14. Boys undergo these changes later, usually between 12 to 16 years of age. Precocious puberty is diagnosed in girls when sexual development begins before the age of 8; in boys, it is diagnosed when these changes occur before age 9. Recently, medical research has linked vitamin D deficiency to a number of diseases, including cancer, obesity and autoimmune disease. …
Melanoma is a tumor affecting melanocytes, skin cells that produce the dark pigment that gives skin its color. The disease is responsible for approximately 75 percent of skin cancer deaths, with chances of survival directly related to how early the cancer is detected. Current detection methods most commonly rely on visual inspection of the skin, which is highly dependent on individual self-examination and clinical skill. The current study took advantage of the fact that human skin produces numerous airborne chemical molecules known as volatile organic compounds, or VOCs, many of which are odorous. …
Babies may be able to show sympathy before their first birthday, according to a new study in which 10-month-olds preferred the victims rather than the aggressors in a bullying encounter. The research, published June 12 in the journal PLOS ONE, is the first to find evidence of possible sympathy in children younger than toddlers, the researchers said. Sympathy is the feeling of concern for others. Because 10-month-olds can't yet express sympathy verbally, Kyoto University researcher Shoji Itakura and colleagues turned to a common tactic in baby-brain research: using simple animations to determine what infants prefer. They showed 40 babies an animation of a blue ball and a yellow cube. Half of the infants watched a short clip in which the blue ball chased the yellow cube around the screen, hitting it seven times before finally squishing it against a wall. The other half of the group saw the same movements, including the squishing, but the two shapes moved independently without interacting. In some cases, the “bully” and “victim” roles were swapped, so that the yellow cube was the bad guy. After watching the show, the babies were shown a real yellow cube and a real blue ball, and given the chance to reach for one of the objects. In cases where the babies had seen one shape beating up on the other, they overwhelmingly reached for the victim, 16 out of 20 times. In comparison, when the shapes hadn't interacted, the babies' choices were basically random nine went for the shape that had gotten squished, and the other 11 went for the nonsquished shape. Picking the victim The results could have simply indicated that babies preferred to steer clear of a nasty character, not that they felt sympathy for the bullied one. To rule out that possibility, the researchers conducted a second experiment with 24 babies, also 10 months old. These babies saw a show nearly identical to the first, except there was a third character: a red cylinder. The red cylinder was a neutral presence on-screen, neither bullying nor being bullied. After watching the animation, the babies were again given a choice of two toys. Half could pick between the “victim” shape and the neutral shape, while the other half got to choose between the bullying shape and the neutral shape. This time, 10 out of 12 babies given the neutral-or-bully option went with the neutral cylinder. Meanwhile, of the 12 given the neutral-or-victim option, 10 picked the victim. In other words, even when there was no mean character present that a baby might want to avoid, the babies still picked the victim. It goes too far to call this proof of sympathy, said Kiley Hamlin, an infant cognition researcher at the University of British Columbia who was not involved in the study. Nevertheless, Hamlin told LiveScience, the findings are “a great first step” in establishing the development of sympathy. Previously, Hamlin has reported that babies as young as 8 months old prefer to see wrongdoers punished rather than treated nicely. Brainy babies Some researchers have raised concerns about the kinds of animations used in infant cognition studies, arguing that babies might be marking their preferences based on extraneous information, like whether one character bounces or moves differently than the others. Itakura and colleagues aimed to control for those concerns by making sure their character shapes moved with the same speed and consistency. “They did a great job controlling for things like movement and amount of color on the stage,” Hamlin said. Though more studies will be needed to nail down babies' motivations for preferring victims of aggression, Hamlin said anecdotes suggest that even young babies notice others in distress, and seem bothered by that distress. “This is a nice way of saying, 'Okay, this is a far more abstract situation, is this something that 10-month-olds are noticing and responding to?” Hamlin said. “It seems to be that case that they are.” Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.source : http://www.foxnews.com/health/2013/06/13/babies-have-sympathy-for-bully-victims-study-suggests/
By substituting healthy vegetable fats — such as olive and canola oils, nuts, seeds and avocados — for animal fats and carbohydrates, men with the disease had a markedly lower risk of developing lethal prostate cancer and dying from other causes, according to the study. The research, involving nearly 4,600 men with non-metastatic prostate cancer, could help with the development of dietary guidelines for men with the disease. While prostate cancer affects millions of men around the world, little is known about the relationship between patients’ diets following their diagnosis and progression of the disease. …
"The active substances present in African medicinal plants may be capable of killing off tumor cells that are resistant to more than one drug. …
The cells, called Multi-lineage Stress-Enduring (Muse-AT) stem cells from fat, or adipose, tissue, were discovered by "scientific accident" when a piece of equipment failed in the lab, killing all the stem cells in the experiment except for the Muse-AT cells. The research team further discovered that not only are Muse-AT cells able to survive severe stress, they may even be activated by it, said study senior author Gregorio Chazenbalk, an associate researcher with UCLA Obstetrics and Gynecology…
The Side-Out Foundation’s pilot study is part of a cutting-edge approach to personalized medicine that looks beyond genomic analysis alone to combine it with what some say is the next frontier in targeted therapy: proteomics. The pilot study is the first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. The trial was announced at the annual meeting of the American Society of Clinical Oncology and is expected to expand into phase two this month. Standard chemotherapy had failed the 25 women who participated in the 2.5-year pilot study, says study co-author Emanuel "Chip" Petricoin, co-director of George Mason’s Center for Applied Proteomics and Molecular Medicine (CAPMM)…